■已经建立了肠道微生物与心血管疾病(CVD)之间的关联,但是潜在的机制在很大程度上仍然未知。
■我们对男性代谢综合征(METSIM)基于人群的10,194名芬兰男性(年龄=57.65±7.12岁)队列中获得的横断面数据进行了二次分析。我们测试了循环肠道微生物衍生代谢物的水平作为CVD的预测因子,缺血性脑血管意外(CVA),心肌梗死(MI)。使用Kaplan-Meier方法估计参与者从首次门诊就诊到出现不良结局的时间。使用Cox比例风险模型评估代谢物水平与结果之间的关联。
■在200个月的中位随访期间,979名参与者经历了CVD,397经验丰富的CVA,和548经验丰富的MI。在对传统风险因素进行调整并校正多重比较后,琥珀酸的血浆水平较高[四分位数4vs.四分位数1;调整后的危险比,aHR=1.30,(置信区间(CI),1.10-1.53)p=0.0003,调整后p=0.01]与CVD风险显著相关。熊去氧胆酸(UDCA)的高血浆水平(四分位数3vs.四分位数1);[aHR=1.68,(CI,1.26-2.2);p=0.0003,调整。p=0.01]与较高的CVA风险相关。此外,作为连续变量,琥珀酸盐与CVD风险降低10%相关[aHR=0.9;(CI,0.84~0.97);p=0.008],MI风险降低15%[aHR=0.85,(CI,0.77~0.93);p=0.0007].
■肠道微生物衍生代谢物,琥珀酸盐,熊去氧胆酸与CVD有关,MI,还有CVA,分别。调节肠道微生物可以代表用于调节CVD和CVA的潜在治疗靶标。
UNASSIGNED: An association between gut microbes and cardiovascular disease (CVD) has been established, but the underlying mechanisms remain largely unknown.
UNASSIGNED: We conducted a secondary analysis of the cross-sectional data obtained from the Metabolic Syndrome in Men (METSIM) population-based cohort of 10,194 Finnish men (age = 57.65 ± 7.12 years). We tested the levels of circulating gut microbe-derived metabolites as predictors of CVD, ischemic cerebrovascular accident (CVA), and myocardial infarction (MI). The Kaplan-Meier method was used to estimate the time from the participants\' first outpatient clinic visit to the occurrence of adverse outcomes. The associations between metabolite levels and the outcomes were assessed using Cox proportional hazard models.
UNASSIGNED: During a median follow-up period of 200 months, 979 participants experienced CVD, 397 experienced CVA, and 548 experienced MI. After adjusting for traditional risk factors and correcting for multiple comparisons, higher plasma levels of succinate [quartile 4 vs. quartile 1; adjusted hazard ratio, aHR = 1.30, (confidence interval (CI), 1.10-1.53) p = 0.0003, adjusted p = 0.01] were significantly associated with the risk of CVD. High plasma levels of ursodeoxycholic acid (UDCA) (quartile 3 vs. quartile 1); [aHR = 1.68, (CI, 1.26-2.2); p = 0.0003, adj. p = 0.01] were associated with a higher risk of CVA. Furthermore, as a continuous variable, succinate was associated with a 10% decrease in the risk of CVD [aHR = 0.9; (CI, 0.84-0.97); p = 0.008] and a 15% decrease in the risk of MI [aHR = 0.85, (CI, 0.77-0.93); p = 0.0007].
UNASSIGNED: Gut microbe-derived metabolites, succinate, and ursodeoxycholic acid were associated with CVD, MI, and CVA, respectively. Regulating the gut microbes may represent a potential therapeutic target for modulating CVD and CVA.